Soleno Therapeutics, Inc. (SLNO)
53.01
+0.02
(+0.04%)
USD |
NASDAQ |
May 15, 16:00
53.02
+0.01
(+0.02%)
After-Hours: 20:00
Soleno Therapeutics Enterprise Value : 2.562B for May 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Neurocrine Biosciences, Inc. | 15.02B |
| Nektar Therapeutics | 796.59M |
| XOMA Royalty Corp. | 573.43M |
| Apellis Pharmaceuticals, Inc. | 5.322B |
| Forian, Inc. | 36.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.38M |
| Revenue (Quarterly) | 94.60M |
| Total Expenses (Quarterly) | 63.23M |
| EPS Diluted (Quarterly) | 0.5913 |
| Gross Profit Margin (Quarterly) | 98.73% |
| Profit Margin (Quarterly) | 33.17% |
| Earnings Yield | 3.32% |
| Operating Earnings Yield | 3.17% |
| Normalized Earnings Yield | 3.400 |